USP9X and prostate cancer: Interestingly, the treatment with Tetra(HPRG)-Fam alone induced an increased viability both in prostate cancer (Figure 5a, 24 h: ~120% of CTRL: ** p < 0.01; Figure 5d, 48 h: up to ~130% of CTRL: *** p < 0.001) and endothelial cells (Figure 5c, 24 h: ~130% of CTRL: * p < 0.05; Figure 5f, 48 h: ~140% of CTRL: ** p < 0.01) cells, while no significant changes in cell viability were detected in neuroblastoma cells for both 24 h (Figure 5b) and 48 h (Figure 5d) of incubation.